NYSE · DHR
Healthcare · Medical - Diagnostics & Research
$209.36
Up+$6.04 (+2.97%)
Updated Sep 16, 2026, 10:59 AM
SID Score
5.8/10
Composite research score
Smart Money
51/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
DHR closed at $209.36 after 20 trading sessions, up 4.90% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $203.08 | $209.55 | $202.6201 | $209.36 | 3.51M |
| Sep 14, 2026 | $202.48 | $203.81 | $199.09 | $203.25 | 3.43M |
| Sep 11, 2026 | $201.99 | $202.68 | $199.16 | $200.14 | 3.63M |
| Sep 10, 2026 | $202.33 | $203.10 | $200.34 | $200.53 | 3.02M |
| Sep 9, 2026 | $206.00 | $206.05 | $201.95 | $204.85 | 2.77M |
| Sep 8, 2026 | $205.00 | $207.84 | $202.12 | $205.23 | 3.28M |
| Sep 4, 2026 | $207.19 | $208.70 | $205.23 | $207.66 | 2.9M |
| Sep 3, 2026 | $210.51 | $213.13 | $206.05 | $211.03 | 2.42M |
| Sep 2, 2026 | $207.77 | $212.7793 | $206.10 | $209.91 | 2.95M |
| Sep 1, 2026 | $214.74 | $215.00 | $206.55 | $206.93 | 3.15M |
| Aug 31, 2026 | $213.45 | $215.385 | $212.22 | $213.56 | 3.61M |
| Aug 28, 2026 | $215.10 | $217.04 | $212.8502 | $216.07 | 2.86M |
| Aug 27, 2026 | $214.78 | $218.57 | $213.092 | $215.68 | 2.93M |
| Aug 26, 2026 | $213.23 | $216.8499 | $212.81 | $215.36 | 2.53M |
| Aug 25, 2026 | $213.88 | $216.77 | $212.24 | $215.97 | 2.34M |
| Aug 24, 2026 | $218.33 | $218.34 | $213.88 | $215.11 | 2.51M |
| Aug 21, 2026 | $215.58 | $220.25 | $213.46 | $218.85 | 4.7M |
| Aug 20, 2026 | $210.12 | $220.67 | $208.21 | $215.91 | 5.5M |
| Aug 19, 2026 | $203.10 | $212.19 | $202.905 | $211.50 | 5.25M |
| Aug 18, 2026 | $203.97 | $204.23 | $199.49 | $199.58 | 2.29M |
The latest Smart Investors Daily articles mentioning DHR.
DHR research
Company profile and research snapshot.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 22, 2026 | RBC Capital | Outperform | — |
| Jul 22, 2026 | Guggenheim | Buy | — |
| Jul 22, 2026 | Stifel | Buy | — |
| Jul 22, 2026 | TD Cowen | Buy | — |
| Jul 22, 2026 | Wells Fargo | Equal-Weight | — |
Generated Sep 15, 2026, 9:08 PM
Danaher Corporation gained 2.97% today, climbing $6.04 as investors reassess the company's relative value positioning in the market. The modest but positive movement suggests renewed investor interest in the diversified conglomerate, particularly as analysts compare its valuation metrics against peers like ELV.
Bottom line: Danaher's 3% gain appears driven by renewed valuation interest rather than fundamental news, positioning the stock as an attractive entry point for value-conscious investors. While the lack of major catalysts presents near-term risks, the company's defensive characteristics and operational excellence provide a solid foundation for long-term investors to monitor. Watch for upcoming earnings reports and management commentary on capital allocation strategy to confirm whether this valuation re-rating has staying power.
Yahoo · Sep 16, 2026
Donaldson (DCI) has gained 9.1% over the past twelve months and still trades about 20% below its 52-week high. The filtration company behind those numbers sells replacement parts into equipment already in service, and the cash from that stream has been steadily shrinking its share count. The shrinking count is the case for buying the pullback. It is also the part that goes quiet in fiscal 2027.
Yahoo · Sep 15, 2026
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.
Yahoo · Sep 15, 2026
ELV vs. DHR: Which Stock Is the Better Value Option?
SeekingAlpha · Sep 10, 2026
Third Pointâs Q2 2026 13F: portfolio doubled to $4.68B as WBD becomes top holding; new buys include Keysight, Block; exits Meta/Nvidia. See more here.
Interpretive context generated from the platform’s current data sources.
Danaher Corporation shares closed at $203.30, declining 1.12% in the most recent session, per SID market data. Over the trailing one-month period, DHR has been essentially flat with a marginal loss of 0.31%, while the three-month return stands at a positive 12.85%, indicating meaningful medium-term recovery. However, the stock remains down 11.79% over the past twelve months, underperforming the broader healthcare sector. Technically, DHR trades just above its 50-day moving average of $202.49 and its 200-day moving average of $199.09, per Massive/Polygon data. The 14-day relative strength index has dropped to 29.8, placing the stock in oversold territory and suggesting recent selling pressure has been significant. Danaher carries a beta of 0.923, indicating slightly lower volatility than the broader market. Average daily trading volume stands at approximately 4.18 million shares, reflecting consistent institutional liquidity.
Danaher Corporation currently trades at a price-to-earnings ratio of 47.14, a notable premium relative to broader healthcare sector averages, per SID market data. The PEG ratio stands at 14.87, suggesting that the stock's earnings growth rate does not proportionally justify its elevated P/E multiple at current levels. The company's price-to-book ratio is 3.23, according to SEC filings, reflecting the significant goodwill and intangible assets accumulated through Danaher's acquisition-driven growth strategy. The dividend yield sits at approximately 0.53%, indicating that Danaher prioritizes capital reinvestment and strategic acquisitions over shareholder returns via income distribution. With a market capitalization of approximately $166.5 billion, Danaher remains one of the largest diversified life sciences and diagnostics companies globally. These valuation metrics collectively position DHR at a premium tier within the healthcare sector, consistent with the company's high-quality compounder reputation among institutional investors.
Danaher Corporation's composite smart money score stands at 51 out of 100, reflecting a neutral overall signal, per SID market data. The institutional component scores a perfect 25 out of 25, indicating overwhelming institutional ownership and conviction in the name. In contrast, the insider score registers at just 4.9 out of 25, despite notable recent activity — SEC Form 4 filings reveal 20 insider transactions over the past 90 days, comprising 17 purchases and only 3 sales. This buy-to-sell ratio of nearly 6-to-1 suggests insiders view current price levels as attractive. The dark pool activity score of 8.5 out of 25 points to moderate off-exchange trading interest, while the congressional trading score of 12.8 out of 25 indicates middling activity among congressional members, according to 13F institutional filings and public disclosure records. The divergence between strong institutional conviction and the relatively low insider composite score warrants monitoring as additional filings are disclosed in coming quarters.
Danaher Corporation has delivered consecutive earnings beats across its three most recently reported quarters, according to company earnings reports. In the most recent quarter, the company posted earnings per share of $1.94 against a consensus estimate of $1.84, representing a positive surprise of $0.10. The prior quarter saw EPS of $2.06 versus expectations of $1.94, a beat of $0.12, while the quarter before that delivered $2.23 against a $2.17 estimate. This consistent pattern of outperformance demonstrates operational execution and effective cost management. The upcoming quarter carries an analyst consensus estimate of $2.17 per share, with results expected on January 27, per analyst estimates. The sequential decline in reported EPS from $2.23 to $1.94 over recent quarters reflects seasonal patterns typical of Danaher's business mix across life sciences, diagnostics, and environmental solutions segments rather than fundamental deterioration.
Wall Street consensus on Danaher Corporation remains predominantly constructive, with the majority of recent analyst actions reaffirming bullish positions, per SID consensus data. On July 22, 2026, four out of five firms issuing ratings maintained positive stances: Guggenheim, Stifel, and TD Cowen each reiterated Buy ratings, while RBC Capital reaffirmed its Outperform rating, according to Wall Street analyst reports. Wells Fargo was the sole neutral voice, maintaining its Equal-Weight rating. Notably, none of the five analysts downgraded their recommendations, and no price target reductions were disclosed in the latest round of coverage updates. The cluster of reaffirmations on the same date likely corresponds to post-earnings analysis following the company's quarterly results. The four-to-one ratio of bullish-to-neutral ratings reflects broad institutional confidence in Danaher's long-term positioning within life sciences and diagnostics, even as the stock trades at elevated valuation multiples relative to near-term earnings growth.
The latest Smart Investors Daily articles mentioning DHR.
